Ultimate fate of oncology drugs approved by the US food and drug administration without a randomized trial

Journal of Clinical Oncology

Volumn 27, Issue 36, 2009, Pages 6243-6250

  Tsimberidou, Apostolia Maria ^a   Braiteh, Fadi ^a   Stewart, David J ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ALTRETAMINE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; ASPARAGINASE; ASPARAGINASE MACROGOL; BEXAROTENE; BLEOMYCIN; BORTEZOMIB; BUSULFAN; CISPLATIN; CLADRIBINE; CYTOTOXIC AGENT; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEFITINIB; GEMTUZUMAB OZOGAMICIN; IFOSFAMIDE; IRINOTECAN; METHOXSALEN; MITOMYCIN; PENTOSTATIN; RECOMBINANT INTERLEUKIN 2; RETINOIC ACID; RITUXIMAB; TEMOZOLOMIDE; TOSITUMOMAB; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LEUKEMIA; CANCER REGISTRY; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLON CANCER; CUTANEOUS T CELL LYMPHOMA; DISEASE FREE SURVIVAL; DRUG APPROVAL; DRUG CAPSULE; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FOLLICULAR LYMPHOMA; FOOD AND DRUG ADMINISTRATION; GERM CELL TESTICULAR CANCER; GLIOBLASTOMA; HAIRY CELL LEUKEMIA; HEPATITIS B; HEPATITIS C; HUMAN; INFORMATION RETRIEVAL; KAPOSI SARCOMA; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MEDLINE; MUTATION; MYELOMA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVARY CANCER; PANCREAS CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; REVIEW; STOMACH CANCER; TESTIS CANCER; TREATMENT RESPONSE; METHODOLOGY; UNITED STATES;

ANTINEOPLASTIC AGENTS; DRUG APPROVAL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 74949139051     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.6018     Document Type: Review

References (64)

1. Hirschfeld S, Pazdur R: Oncology drug development: United States Food and Drug Administration perspective. Crit Rev Oncol Hematol 42:137-143, 2002
2. Markman M: Recent reminders of why the gold standard for clinical research in oncology is the well-designed and conducted randomized phase III trial. Curr Oncol Rep 6:421-422, 2004
3. Stewart DJ, Kurzrock R: Cancer: The road to Amiens. J Clin Oncol 27:328-333, 2009
4. Burris III HA, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997
5. Cohen MH, Gootenberg J, Keegan P, et al: FDA drug approval summary: Bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 12:356-361, 2007
6. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966, 2007
7. Cohen MH, Gootenberg J, Keegan P, et al: FDA drug approval summary: Bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12:713-718, 2007
8. Kane RC, Farrell AT, Saber H, et al: Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 12:7271-7278, 2006
9. Cohen MH, Johnson JR, Pazdur R: Food and Drug Administration Drug approval summary: Temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res 11:6767-6771, 2005
10. Dagher R, Li N, Abraham S, et al: Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. Clin Cancer Res 10:8147-8151, 2004
11. Brave M, Dagher R, Farrell A, et al: Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer. Oncology (Williston Park) 20:1401-1404, 1410, 2006; discussion 1410- 11:1415-1416, 2006
12. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040-2048, 2007
13. Sibbald B, Roland M: Understanding controlled trials. Why are randomised controlled trials important? BMJ 316:201, 1998
14. Brown ML, Gersh BJ, Holmes DR, et al: From randomized trials to registry studies: Translating data into clinical information. Nat Clin Pract Cardiovasc Med 5:613-620, 2008
15. Simon SD: Is the randomized clinical trial the gold standard of research? J Androl 22:938-943, 2001
16. Wilcox RA, Djulbegovic B, Moffitt HL, et al: Randomized trials in oncology stopped early for benefit. J Clin Oncol 26:18-19, 2008
17. Goitein M, Cox JD: Should randomized clinical trials be required for proton radiotherapy? J Clin Oncol 26:175-176, 2008
18. Hernan MA, Hernandez-Diaz S, Robins JM: A structural approach to selection bias. Epidemiology 15:615-625, 2004
19. US Food and Drug Administration. http://www.accessdata.fda.gov/scripts/ cder/drugsatfda/index.cfm
20. National Comprehensive Cancer Network. http://www.nccn.org/
21. National Cancer Institute: Physician Data Query. http://www.cancer.gov/ cancertopics/pdq
22. Samuels ML, Johnson DE, Holoye PY: Continuous intravenous bleomycin (NSC-125066) therapy with vinblastine (NSC-49842) in stage III testicular neoplasia. Cancer Chemother Rep 59:563-570, 1975
23. De Jager RL, Magill GB, Golbey RB, et al: Combination chemotherapy with mitomycin C, 5-fluorouracil, and cytosine arabinoside in gastrointestinal cancer. Cancer Treat Rep 60:1373-1375, 1976
24. Lloyd RE, Jones SE, Salmon SE, et al: Combination chemotherapy with adriamycin (NSC-123127) and cyclophosphamide (NSC-26271) for solid tumors: A phase II trial. Cancer Treat Rep 60:77-83, 1976
25. Barlow JJ, Piver MS, Chuang JT, et al: Adriamycin and bleomycin, alone and in combination, in gynecologic cancers. Cancer 32:735-743, 1973
26. National Cancer Institute: Drug Information Summaries.http://cancer.gov/ cancertopics/druginfo/alphalist
27. Ertel IJ, Nesbit ME, Hammond D, et al: Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: A report from Childrens Cancer Study Group. Cancer Res 39:3893-3896, 1979
28. Quesada JR, Reuben J, Manning JT, et al: Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 310:15-18, 1984
29. Foon KA, Maluish AE, Abrams PG, et al: Recombinant leukocyte A interferon therapy for advanced hairy cell leukemia: Therapeutic and immunologic results. Am J Med 80:351-356, 1986
30. Jacobs AD, Champlin RE, Golde DW: Recombinant alpha-2-interferon for hairy cell leukemia. Blood 65:1017-1020, 1985
31. Santana VM, Mirro J Jr, Harwood FC, et al: A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. J Clin Oncol 9:416-422, 1991
32. Von Hoff DD, Rotheberg ML, Pitot HC, et al: Irinotecan therapy for patients with previously treated metastatic colorectal cancer: Overall results of FDA-reviewed pivotal US clinical trials. Proc Am Soc Clin Oncol 16:2208a, 1997 (abstr 803)
33. Andersson BS, Kashyap A, Gian V, et al: Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: A phase II study. Biol Blood Marrow Transplant 8:145-154, 2002
34. Cohen MH, Williams GA, Sridhara R, et al: United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 10:1212-1218, 2004
35. Cohen MH, Williams GA, Sridhara R, et al: FDA drug approval summary: Gefitinib (ZD1839) (Iressa) tablets. Oncologist 8:303-306, 2003
36. Dagher R, Johnson J, Williams G, et al: Accelerated approval of oncology products: A decade of experience. J Natl Cancer Inst 96:1500-1509, 2004
37. Di Lorenzo G: Update on classic Kaposi sarcoma therapy: New look at an old disease. Crit Rev Oncol Hematol 68:242-249, 2008
38. Kurzrock R, Talpaz M, Gutterman JU: Hairy cell leukaemia: Review of treatment. Br J Haematol 79:17-20, 1991 (suppl 1)
39. Golomb HM: Hairy cell leukemia: Treatment successes in the past 25 years. J Clin Oncol 26: 2607-2609, 2008
40. Dinndorf PA, Gootenberg J, Cohen MH, et al: FDA drug approval summary: Pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist 12:991-998, 2007
41. US Food and Drug Administration: http://www.fda.gov/AboutFDA/ CentersOffices/CDER/ucm091745.htm
42. Cohen MH, Johnson JR, Pazdur R: U.S. Food and Drug Administration Drug Approval Summary: Conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clin Cancer Res 11:12-19, 2005
43. Druker BJ, Guilhot F, O'Brien SG, et al: Fiveyear follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417, 2006
44. IRESSA Access Program. http://www.iressaus.com/prof.asp
45. Maisey N, Chau I, Cunningham D, et al: Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol 20:3130-3136, 2002
46. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
47. Markman M: New, expanded, and modified use of approved antineoplastic agents in ovarian cancer. Oncologist 12:186-190, 2007
48. E-Medicine from WebMD: Kaposi Sarcoma: TreatmentandMedication.http:// emedicine.medscape.com/article/279734-treatment.
49. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58:71-96, 2008
50. Cancer Research UK: Cancer Worldwide. http://info.cancerresearchuk.org/ cancerstats/geographic/world/incidence/
51. Thatcher N, Chang A, Parikh P, et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-1537, 2005
52. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al: Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 24:5034-5042, 2006
53. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
54. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005
55. Braiteh F, Kurzrock R: Uncommon tumors and exceptional therapies: Paradox or paradigm? Mol Cancer Ther 6:1175-1179, 2007
56. Johnson JR, Williams G, Pazdur R: End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21:1404-1411, 2003
57. Chau I, Norman AR, Cunningham D, et al: Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 22:2395-2403, 2004
58. Zander AR, Kroger N, Schmoor C, et al: High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: First results of a randomized trial. J Clin Oncol 22:2273-2283, 2004
59. Winer EP, Berry DA, Woolf S, et al: Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and leukemia group B trial 9342. J Clin Oncol 22:2061-2068, 2004
60. Durie BG, Jacobson J, Barlogie B, et al: Magnitude of response with myeloma frontline therapy does not predict outcome: Importance of time to progression in southwest oncology group chemotherapy trials. J Clin Oncol 22:1857-1863, 2004
61. Shanafelt TD, Loprinzi C, Marks R, et al: Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer? J Clin Oncol 22: 1966-1974, 2004
62. Piantadosi S: Bias and random error, in Piantadosi S (ed): Clinical Trials: A Methodologic Perspective. New York, NY, John Wiley & Sons Inc, 1997, pp 106-126
63. Stadtmauer EA, O'Neill A, Goldstein LJ, et al: Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med 342:1069-1076, 2000
64. Booth CM, Cescon DW, Wang L, et al: Evolution of the randomized controlled trial in oncology over three decades. J Clin Oncol 26:5458-5464, 2008